Last quarter (Q2 2022), HemoGenyx Pharmaceuticals Plc's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, HemoGenyx Pharmaceuticals Plc's net income was £―. See HemoGenyx Pharmaceuticals Plc’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	£ 0.00	£ 0.00	£ 0.00
Cost of Revenue	-	-	£ 283.65K	£ 267.06K	£ 421.82K	£ 348.27K
Gross Profit	-	-	£ -283.65K	£ -267.06K	£ -421.82K	£ -348.27K
Operating Expense	-	£ 5.53M	£ 2.55M	£ 1.95M	£ 1.25M	£ 1.33M
Operating Income	-	£ -5.53M	£ -2.83M	£ -2.22M	£ -1.67M	£ -1.68M
Net Non Operating Interest Income Expense	-	£ 10.57K	£ 2.58M	£ -29.87K	£ -17.14K	£ 2.60K
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	£ -3.99M	£ -5.11M	£ -2.10M	£ -1.49M	£ -1.59M
Tax Provision	-	-	-	£ 0.00	£ -35.00K	£ -43.75K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -3.98M	£ -5.10M	£ -2.08M	£ -1.45M	£ -1.54M
Basic EPS	-	£ -0.01	£ -0.01	£ >-0.01	£ >-0.01	£ >-0.01
Diluted EPS	-	£ -0.01	£ -0.01	£ >-0.01	£ >-0.01	£ >-0.01
Basic Average Shares	-	£ 979.75M	£ 773.95M	£ 414.83M	£ 360.72M	£ 360.13M
Diluted Average Shares	-	£ 979.75M	£ 773.95M	£ 414.83M	£ 360.72M	£ 360.13M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	£ 0.00	£ 45.28K
Total Expenses	-	£ 5.53M	£ -2.83M	£ 2.22M	£ 1.67M	£ 1.68M
Net Income From Continuing And Discontinued Operation	-	£ -3.98M	£ -5.10M	£ -2.08M	£ -1.45M	£ -1.54M
Normalized Income	-	£ -3.23M	£ -4.31M	£ -2.08M	£ -1.45M	£ -1.54M
Interest Expense	-	-	-	£ 33.24K	£ 31.33K	£ 1.78K
EBIT	-	£ -3.99M	£ -2.51M	£ -2.06M	£ -1.46M	£ -1.59M
EBITDA	-	£ -3.79M	£ -2.51M	£ -1.96M	£ -1.36M	£ -1.53M

Currency in GBP

HemoGenyx Pharmaceuticals Plc Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing